02.04.08
AMRI has purchased FineKem Laboratories Pvt. Ltd., a manufacturing facility located in Aurangabad, India. This acquisition will add to the company’s ability to make custom pilot scale intermediates in India, which is expected to begin 2Q2008, and also adds another compound, ISMN (Isosorbide Mononitrate), to AMRI’s generics portfolio.
In the next few months, AMRI plans to upgrade the existing facilities to make them compliant with FDA regulations for manufacturing clinical trial materials and commercial drug substances.
FineKem’s managing director, Rakesh Doshi, will join AMRI India PVT Ltd. as executive director and chief operating officer reporting to Dr. Prasad Raje, managing director of AMRI’s current Aurangabad and Navi Mumbai facilities.
“We are pleased to announce the addition of this new product offering,” said AMRI chairman, president and chief executive officer, Thomas E. D'Ambra, Ph.D. “As we continue to explore and expand the ability of AMRI to provide value and flexibility around the globe, the purchase of this site increases the cost-competitive solutions available to our customers for their outsourcing needs.”
In the next few months, AMRI plans to upgrade the existing facilities to make them compliant with FDA regulations for manufacturing clinical trial materials and commercial drug substances.
FineKem’s managing director, Rakesh Doshi, will join AMRI India PVT Ltd. as executive director and chief operating officer reporting to Dr. Prasad Raje, managing director of AMRI’s current Aurangabad and Navi Mumbai facilities.
“We are pleased to announce the addition of this new product offering,” said AMRI chairman, president and chief executive officer, Thomas E. D'Ambra, Ph.D. “As we continue to explore and expand the ability of AMRI to provide value and flexibility around the globe, the purchase of this site increases the cost-competitive solutions available to our customers for their outsourcing needs.”
